Key Financial Data Of Group

Delta-Fly Pharma, Inc. - Filing #7296920

Concept 2024-04-01 to
2024-09-30
As at
2024-09-30
As at
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2023-09-30
As at
2023-09-30
Key financial data of group
Business results of group
Ordinary profit (loss)
-915,896,000 JPY
-1,426,891,000 JPY
-599,036,000 JPY
Net assets
315,508,000 JPY
1,232,656,000 JPY
402,835,000 JPY
Total assets
425,820,000 JPY
1,474,155,000 JPY
490,779,000 JPY
Basic earnings (loss) per share
-111.44
-198.78
-91.92
Diluted earnings per share
Equity-to-asset ratio
0.739 xbrli:pure
0.836 xbrli:pure
0.818 xbrli:pure
Net cash provided by (used in) operating activities
-1,066,826,000 JPY
-1,279,615,000 JPY
-619,048,000 JPY
Net cash provided by (used in) investing activities
JPY
207,000 JPY
918,000 JPY
Net cash provided by (used in) financing activities
JPY
1,853,195,000 JPY
211,138,000 JPY
Cash and cash equivalents
349,122,000 JPY
1,417,062,000 JPY
436,811,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.